MANKIND PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,237 INR | +3.01% |
|
-3.38% | +12.82% |
Valuation
| Fiscal Period: March | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 869,798 | - | - |
| Enterprise Value (EV) 1 | 844,545 | 826,378 | 806,346 |
| P/E ratio | 47.5 x | 39.9 x | 33.2 x |
| Yield | 0.32% | 0.45% | 0.59% |
| Capitalization / Revenue | 8.44 x | 7.46 x | 6.58 x |
| EV / Revenue | 8.19 x | 7.08 x | 6.1 x |
| EV / EBITDA | 33.9 x | 28.1 x | 23.3 x |
| EV / FCF | 56.7 x | 46.1 x | 36.7 x |
| FCF Yield | 1.76% | 2.17% | 2.73% |
| Price to Book | 9.41 x | 7.65 x | 6.35 x |
| Nbr of stocks (in thousands) | 400,588 | - | - |
| Reference price 2 | 2,171 | 2,171 | 2,171 |
| Announcement Date | - | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 87,494 | 103,113 | 116,643 | 132,256 |
| EBITDA 1 | - | 19,006 | 24,937 | 29,450 | 34,602 |
| EBIT 1 | - | 15,747 | 21,049 | 25,399 | 30,200 |
| Operating Margin | - | 18% | 20.41% | 21.78% | 22.83% |
| Earnings before Tax (EBT) 1 | - | 16,712 | 23,287 | 27,785 | 33,247 |
| Net income 1 | 14,335 | 12,819 | 18,298 | 21,751 | 26,165 |
| Net margin | - | 14.65% | 17.75% | 18.65% | 19.78% |
| EPS 2 | 35.78 | 32.00 | 45.72 | 54.45 | 65.32 |
| Free Cash Flow 1 | - | 10,243 | 14,885 | 17,942 | 21,979 |
| FCF margin | - | 11.71% | 14.44% | 15.38% | 16.62% |
| FCF Conversion (EBITDA) | - | 53.89% | 59.69% | 60.92% | 63.52% |
| FCF Conversion (Net income) | - | 79.91% | 81.35% | 82.49% | 84% |
| Dividend per Share 2 | - | - | 6.850 | 9.683 | 12.82 |
| Announcement Date | 8/1/22 | 5/30/23 | - | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|
| Net sales 1 | 25,786 | 26,998 | 24,214 | 24,228 |
| EBITDA 1 | 6,548 | 6,987 | 5,822 | 5,585 |
| EBIT 1 | 5,675 | 5,706 | 4,347 | 4,155 |
| Operating Margin | 22.01% | 21.13% | 17.95% | 17.15% |
| Earnings before Tax (EBT) 1 | 6,245 | 6,229 | 4,984 | 4,776 |
| Net income 1 | 4,869 | 5,176 | 4,194 | 3,823 |
| Net margin | 18.88% | 19.17% | 17.32% | 15.78% |
| EPS 2 | 12.14 | 11.00 | 9.867 | 9.350 |
| Dividend per Share | - | - | - | - |
| Announcement Date | 8/2/23 | - | - | - |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | - | 25,253 | 43,420 | 63,452 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | 10,243 | 14,885 | 17,942 | 21,979 |
| ROE (net income / shareholders' equity) | - | 18.9% | 21.3% | 21.1% | 20.9% |
| ROA (Net income/ Total Assets) | - | 13.6% | 17.4% | 18.3% | 18.2% |
| Assets 1 | - | 94,317 | 105,403 | 118,963 | 143,389 |
| Book Value Per Share 2 | - | 186.0 | 231.0 | 284.0 | 342.0 |
| Cash Flow per Share 2 | - | 45.30 | 54.90 | 64.50 | 75.60 |
| Capex 1 | - | 7,890 | 4,882 | 5,187 | 5,349 |
| Capex / Sales | - | 9.02% | 4.73% | 4.45% | 4.04% |
| Announcement Date | 8/1/22 | 5/30/23 | - | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
2,171
INR
Average target price
2,186
INR
Spread / Average Target
+0.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.82% | 10.42B | |
| +32.36% | 695B | |
| +26.51% | 568B | |
| -4.40% | 361B | |
| +19.46% | 330B | |
| +3.50% | 283B | |
| +17.08% | 239B | |
| +8.00% | 204B | |
| -7.53% | 198B | |
| +8.62% | 168B |
- Stock Market
- Equities
- MANKIND Stock
- Financials Mankind Pharma Limited